Considering Cell Therapy Product "Good Manufacturing Practice" Status

被引：34

作者：

Bedford, Patrick ^{[1
]}

Jy, Juliana ^{[1
]}

Collins, Lucas ^{[1
]}

Keizer, Steven ^{[1
]}

机构：

[1] CCRM, Toronto, ON, Canada

来源：

FRONTIERS IN MEDICINE | 2018年 / 5卷

关键词：

cell therapy; clinical trials; regulatory; manufacturing; good manufacturing practices; international perspective;

D O I：

10.3389/fmed.2018.00118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 6 条

[1]

[Anonymous], 2015, HLTH CANADA GUIDANCE

[2]

George Bobby, 2011, Perspect Clin Res, V2, P94, DOI 10.4103/2229-3485.83228

[3] Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts [J].

Hartmann, Jessica ;

Schuessler-Lenz, Martina ;

Bondanza, Attilio ;

Buchholz, Christian J. .

EMBO MOLECULAR MEDICINE, 2017, 9 (09) :1183-1197

[4] Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments [J].

Isasi, Rosario ;

Rahimzadeh, Vasiliki ;

Charlebois, Kathleen .

APPLIED AND TRANSLATIONAL GENOMICS, 2016, 11 :27-39

[5] Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach [J].

Krackhardt, Angela M. ;

Anliker, Brigitte ;

Hildebrandt, Martin ;

Bachmann, Michael ;

Eichmueller, Stefan B. ;

Nettelbeck, Dirk M. ;

Renner, Matthias ;

Uharek, Lutz ;

Willimsky, Gerald ;

Schmitt, Michael ;

Wels, Winfried S. ;

Schuessler-Lenz, Martina .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (04) :513-523

[6] Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan [J].

Yano, Kazuo ;

Watanabe, Natsumi ;

Tsuyuki, Kenichiro ;

Ikawa, Taisuke ;

Kasanuki, Hiroshi ;

Yamato, Masayuki .

REGENERATIVE THERAPY, 2015, 1 :45-56

← 1 →